Yifan Pharmaceutical Co., Ltd.

Symbol: 002019.SZ

SHZ

11.4

CNY

Market price today

  • -36.7729

    P/E Ratio

  • 0.5161

    PEG Ratio

  • 13.89B

    MRK Cap

  • 0.00%

    DIV Yield

Yifan Pharmaceutical Co., Ltd. (002019-SZ) Stock Price & Analysis

Shares Outstanding

1223.61M

Gross Profit Margin

0.47%

Operating Profit Margin

-0.18%

Net Profit Margin

-0.11%

Return on Assets

-0.04%

Return on Equity

-0.05%

Return on Capital Employed

-0.09%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO:Mr. Xian Feng Cheng
Full-time employees:4338
City:Hangzhou
Address:No. 50, Qinshan
IPO:2004-07-13
CIK:

Yifan Pharmaceutical Co., Ltd. produces and sells drugs and medicines in China and internationally. It provides drugs across gynecology, pediatrics, orthopedics, and dermatology therapeutic areas; therapeutic infusion solutions; and pantothenic acid and Provitamin B5 products. The company also provides Chinese traditional medicines, women's health products, and blood tumor drugs. In addition, it offers APIs, including feed additives/animal health products, skin and hair care ingredients, functional food additives, and fine chemicals; and PBAT/PBS biodegradable resins and PVB films. The company was formerly known as Yifan Xinfu Pharmaceutical Co., Ltd. and changed its name to Yifan Pharmaceutical Co., Ltd. in October 2016. Yifan Pharmaceutical Co., Ltd. was founded in 2000 and is based in Hangzhou, China.

General Outlook

In simple terms, Yifan Pharmaceutical Co., Ltd. has 1223.607 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.469% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.181%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.106%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.040% return, is a testament to Yifan Pharmaceutical Co., Ltd.'s adeptness in optimizing resource deployment. Yifan Pharmaceutical Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.054%. Furthermore, the proficiency of Yifan Pharmaceutical Co., Ltd. in capital utilization is underscored by a remarkable -0.086% return on capital employed.

Stock Prices

Yifan Pharmaceutical Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $11.52, while its low point bottomed out at $11.09. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Yifan Pharmaceutical Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing 002019.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 142.79% gauges short-term asset coverage for liabilities. The quick ratio (91.91%) assesses immediate liquidity, while the cash ratio (32.72%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio142.79%
Quick Ratio91.91%
Cash Ratio32.72%

Profitability Ratios

002019.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -16.81% underscores its earnings before tax deductions. The effective tax rate stands at -7.61%, revealing its tax efficiency. The net income per EBT, 63.03%, and the EBT per EBIT, 93.11%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -18.06%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-16.81%
Effective Tax Rate-7.61%
Net Income per EBT63.03%
EBT per EBIT93.11%
EBIT per Revenue-18.06%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.43, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding92
Days of Inventory Outstanding153
Operating Cycle271.51
Days of Payables Outstanding85
Cash Conversion Cycle186
Receivables Turnover3.08
Payables Turnover4.28
Inventory Turnover2.39
Fixed Asset Turnover2.54
Asset Turnover0.38

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.41, and free cash flow per share, -0.02, depict cash generation on a per-share basis. The cash per share value, 0.69, showcases liquidity position. A payout ratio of -0.15 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.11, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.41
Free Cash Flow per Share-0.02
Cash per Share0.69
Payout Ratio-0.15
Operating Cash Flow Sales Ratio0.11
Free Cash Flow to Operating Cash Flow Ratio-0.04
Cash Flow Coverage Ratio0.25
Short Term Coverage Ratio0.40
Capital Expenditure Coverage Ratio0.96
Dividend Paid and Capex Coverage Ratio0.85

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 16.58%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.23, we discern the balance between debt and equity financing. The long-term debt to capitalization, 7.86%, and total debt to capitalization, 18.85%, ratios shed light on its capital structure. An interest coverage of -11.17 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio16.58%
Debt Equity Ratio0.23
Long Term Debt to Capitalization7.86%
Total Debt to Capitalization18.85%
Interest Coverage-11.17
Cash Flow to Debt Ratio0.25
Company Equity Multiplier1.40

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 3.31, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.45, reflects the portion of profit attributed to each share. The book value per share, 6.80, represents the net asset value distributed per share, while the tangible book value per share, 2.48, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share3.31
Net Income Per Share-0.45
Book Value Per Share6.80
Tangible Book Value Per Share2.48
Shareholders Equity Per Share6.80
Interest Debt Per Share1.65
Capex Per Share-0.41

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 4.84%, indicates top-line expansion, while the gross profit growth, -1.88%, reveals profitability trends. EBIT growth, -97.63%, and operating income growth, -97.63%, offer insights into operational profitability progression. The net income growth, -533.39%, showcases bottom-line expansion, and the EPS growth, -509.09%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth4.84%
Gross Profit Growth-1.88%
EBIT Growth-97.63%
Operating Income Growth-97.63%
Net Income Growth-533.39%
EPS Growth-509.09%
EPS Diluted Growth-551.35%
Weighted Average Shares Growth1.75%
Weighted Average Shares Diluted Growth-4.42%
Dividends per Share Growth-17.55%
Operating Cash Flow Growth-25.25%
Free Cash Flow Growth-115.36%
10-Year Revenue Growth per Share158.01%
5-Year Revenue Growth per Share-13.83%
3-Year Revenue Growth per Share-25.88%
10-Year Operating CF Growth per Share54.84%
5-Year Operating CF Growth per Share-70.10%
3-Year Operating CF Growth per Share-68.32%
10-Year Net Income Growth per Share-1063.53%
5-Year Net Income Growth per Share-174.15%
3-Year Net Income Growth per Share-156.63%
10-Year Shareholders Equity Growth per Share629.95%
5-Year Shareholders Equity Growth per Share23.97%
3-Year Shareholders Equity Growth per Share-2.42%
10-Year Dividend per Share Growth per Share15.77%
5-Year Dividend per Share Growth per Share-86.77%
3-Year Dividend per Share Growth per Share-64.30%
Receivables Growth-8.95%
Inventory Growth11.75%
Asset Growth-8.32%
Book Value per Share Growth-7.70%
Debt Growth-7.72%
R&D Expense Growth56.04%
SGA Expenses Growth27.75%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 19,275,067,896.3, captures the company's total value, considering both debt and equity. Income quality, -0.64, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.03, gauges operational efficiency, while the research and development to revenue, 7.38%, highlights investment in innovation. The ratio of intangibles to total assets, 46.46%, indicates the value of non-physical assets, and capex to operating cash flow, -142.85%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value19,275,067,896.3
Income Quality-0.64
Sales General and Administrative to Revenue0.03
Research and Development to Revenue7.38%
Intangibles to Total Assets46.46%
Capex to Operating Cash Flow-142.85%
Capex to Revenue-12.53%
Capex to Depreciation-180.15%
Graham Number8.33
Return on Tangible Assets-8.95%
Graham Net Net-0.71
Working Capital1,063,780,792
Tangible Asset Value3,011,643,153
Net Current Asset Value106,208,329
Average Receivables1,458,899,107
Average Payables359,879,242.5
Average Inventory879,789,022.5
Days Sales Outstanding126
Days Payables Outstanding72
Days of Inventory On Hand155
ROIC0.09%
ROE-0.07%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.05, and the price to book ratio, 2.05, reflect the market's valuation relative to the company's book value. The price to sales ratio, 3.92, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -819.78, and price to operating cash flows, 34.89, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.05
Price to Book Ratio2.05
Price to Sales Ratio3.92
Price Cash Flow Ratio34.89
Price Earnings to Growth Ratio0.52
Enterprise Value Multiple-29.19
Price Fair Value2.05
Price to Operating Cash Flow Ratio34.89
Price to Free Cash Flows Ratio-819.78
Price to Tangible Book Ratio2.17
Enterprise Value to Sales4.79
Enterprise Value Over EBITDA66.63
EV to Operating Cash Flow54.62
Earnings Yield-3.07%
Free Cash Flow Yield-0.84%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Yifan Pharmaceutical Co., Ltd. (002019.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -36.773 in 2024.

What is the ticker symbol of Yifan Pharmaceutical Co., Ltd. stock?

The ticker symbol of Yifan Pharmaceutical Co., Ltd. stock is 002019.SZ.

What is company IPO date?

IPO date of Yifan Pharmaceutical Co., Ltd. is 2004-07-13.

What is company current share price?

Current share price is 11.400 CNY.

What is stock market cap today?

The market cap of stock today is 13894299001.000.

What is PEG ratio in 2024?

The current 0.516 is 0.516 in 2024.

What is the number of employees in 2024?

In 2024 the company has 4338.